Outpatient blind percutaneous liver biopsy in infants and children: is it safe?

Mortada H El-Shabrawi, Hanaa M El-Karaksy, Sawsan H Okahsa, Naglaa M Kamal, Gamal El-Batran, Khaled A Badr, Mortada H El-Shabrawi, Hanaa M El-Karaksy, Sawsan H Okahsa, Naglaa M Kamal, Gamal El-Batran, Khaled A Badr

Abstract

Background/aim: We aim to investigate the safety of outpatient blind percutaneous liver biopsy (BPLB) in infants and children with chronic liver disease (CLD).

Patients and methods: BPLB was performed as an outpatient procedure using the aspiration Menghini technique in 80 infants and children, aged 2 months to 14 yrs, for diagnosis of their CLD. Patients were divided into three groups: Group 1 (<1 year), group 2 (1-6 yrs), and group 3 (6-14 yrs). The vital signs were closely monitored 1 hr before biopsy, and then 1, 2, 6, and 24 hrs after biopsy. Twenty-four hours pre- and post-biopsy complete blood counts, liver enzymes, prothrombin time (PT), and abdominal ultrasonography, searching for a biopsy-induced hematoma, were done for all patients.

Results: No mortality or major morbidities were encountered after BPLB. The rate of minor complications was 17.5% including irritability or "pain" requiring analgesia in 10%, mild fever in 5%, and drowsiness for >6 hrs due to oversedation in 2.5%. There was a statistically significant rise in the 1-hr post-biopsy mean heart and respiratory rates, but the rise was non-significant at 6 and 24 hrs except for group 2 where heart rate and respiratory rates significantly dropped at 24 hrs. No statistically significant difference was noted between the mean pre-biopsy and the 1, 6, and 24-hrs post-biopsy values of blood pressure in all groups. The 24-hrs post-biopsy mean hemoglobin and hematocrit showed a significant decrease, while the 24-hrs post-biopsy mean total leucocyte and platelet counts showed non-significant changes. The 24-hrs post-biopsy mean liver enzymes were non-significantly changed except the 24-hrs post-biopsy mean PT which was found to be significantly prolonged, for a yet unknown reason(s).

Conclusions: Outpatient BPLB performed by the Menghini technique is safe and well tolerated even in infants and young children. Frequent, close monitoring of patients is strongly recommended to achieve optimal patient safety and avoid potential complications.

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Age groups and percentage of the studied population

References

    1. Lichtman S, Guzman C, Moore D, Weber JL, Roberts EA. Morbidity after percutaneous liver biopsy. Arch Dis Child. 1987;62:901–4.
    1. Bruton OC, Metzger JF Sprinz H. Experience with needle biopsy of the liver in infants and children. Pediatrics. 1955;16:836–41.
    1. Kaye R, Koop CE, Wagner BM, Picou D, Yakovac WC. Needle biopsy of the liver, an aid in the differential diagnosis of prolonged jaundice in infancy. AMA J Dis Child. 1959;98:699–709.
    1. Hong R, Schubert WK. Menghini needle biopsy of the liver. Am J Dis Child. 1960;100:42–6.
    1. Porter M, Riley HD, Jr, Graham H. Needle biopsy of the liver in infants and children. J Pediatr. 1964;65:176–88.
    1. Walker WA, Krivit W, Sharp HL. Needle biopsy of the liver in infancy and childhood.A safe diagnostic aid in liver disease. Pediatrics. 1967;40:946–50.
    1. van Leeuwen DJ, Wilson L, Crowe DR. Liver biopsy in the mid-1990s: Questions and answers. Semin Liver Dis. 1995;15:340–59.
    1. Bravo A, Sheth SG, Chopra S. Liver biopsy. [Last accessed on 2011 Apr 9];N Engl J Med. 2001 344:495–500. Available from: .
    1. Sherlock S. 8th ed. Boston, Melbourne: Blackwell Scientific Publication; 1989. Diseases of the liver and biliary system: Needle biopsy of the liver; pp. 36–48.
    1. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: An audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut. 1995;36:437–41.
    1. Nobili V, Comparcola D, Sartorelli MR, Natali G, Monti L, Falappa P, et al. Blind and ultrasound-guided percutaneous liver biopsy in children. Pediatr Radiol. 2003;33:772–5.
    1. Balistreri WF. Neonatal cholestasis. J Pediatr. 1985;106:171–84.
    1. Brough AJ, Bernstein J. Conjugated hyperbilirubinemia in early infancy.A reassessment of liver biopsy. Hum Pathol. 1974;5:507–16.
    1. Mahal AS, Knauer CM, Gregory PB. Bleeding after liver biopsy: How often and why? Gastroenterology. 1979;76:1192.
    1. Perrault J, McGill DB, Ott BJ, Taylor WF. Liver biopsy: Complications in 1000 inpatients and outpatients. Gastroenterology. 1978;4:103–6.
    1. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy.A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986;2:165–73.
    1. Menghini G. One-second needle biopsy of the liver. Gastroenterology. 1958;35:190–9.
    1. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice.British Society of Gastroenterology. Gut. 1999;45(Suppl 4):41–411.
    1. Klatskin G, Conn HO, editors. Histopathology of the liver. Vol. 1. New York: Oxford University Press; 1993. Techniques; pp. 3–8.
    1. Sporea I, Popescu A, Sirli R. Why, who and how should perform liver biopsy in chronic liver diseases. World J Gastroenterol. 2008;14:3396–402.
    1. Garcia-Tsao G, Boyer JL. Outpatient liver biopsy: How safe is it? Ann Intern Med. 1993;118:150–3.
    1. Brown KE, Janney CG, Brunt EM. Liver biopsy: Indications, technique, complications, and interpretation. In: Bacon BR, Di Bisceglie AM, editors. Liver disease: Diagnosis and management. New York: Churchill Livingstone; 2000. p. 47.
    1. Sparchez Z. Complications after percutaneous liver biopsy in diffuse hepatopathies. Rom J Gastroenterol. 2005;14:379–84.
    1. Friedman LS. Controversies in liver biopsy: Who, where, when, how, why? Curr Gastroenterol Rep. 2004;6:30–6.
    1. McGill DB. Liver biopsy: When, how, by whom, and where? Curr Gastroenterol Rep. 2001;3:19–23.
    1. Minuk GY, Sutherland LR, Wiseman DA, MacDonald FR, Ding DL. Prospective study of the incidence of ultrasound-detected intrahepatic and subcapsular hematomas in patients randomized to 6 or 24 hours of bed rest after percutaneous liver biopsy. Gastroenterology. 1987;92:290–3.
    1. Reddy KR, Schiff ER. Complications of liver biopsy. In: Taylor MB, editor. Gastrointestinal emergencies. 2nd ed. Baltimore: Williams and Wilkins; 1997. pp. 959–68.
    1. Reddy KR, Jeffers LJ. Evaluation of the liver: Liver biopsy and laparoscopy. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Schiff's diseases of the liver. 8th ed. Vol. 1. Philadelphia: Lippincott-Raven; 1999. pp. 245–66.
    1. Sherlock S. Needle biopsy of the liver: A review. J Clin Pathol. 1962;15:291–304.
    1. Ament M. Prospective study of risks of complication in 6,424 procedures in pediatric gastroenterology. Pediatr Res. 1981;15:524.
    1. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci. 1981;26:388–93.
    1. Castera L, Negre I, Samii K, Buffet C. Pain experienced during percutaneous liver biopsy. Hepatology. 1999;30:1529–30.
    1. van Thiel DH, Gavaler JS, Wright H, Tzakis A. Liver biopsy: Its safety and complications as seen at a liver transplant center. Transplantation. 1993;55:1087–90.
    1. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med. 1993;118:96–8.
    1. Hederstrom E, Forsberg L, Floren CH, Prytz H. Liver biopsy complications monitored by ultrasound. J Hepatol. 1989;8:94–8.
    1. Raines DR, Van Heertum RL, Johnson LF. Intrahepatic hematoma: A complication of percutaneous liver biopsy. Gastroenterology. 1974;67:284–9.
    1. Lebensztejn DM, Kaczmarski M, Sobaniec-Łotowska M, Barwijuk-Machała M. Blind liver biopsy in children–diagnostic significance and complications in authors’ own material. Med Sci Monit. 2000;6:1155–8.
    1. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: Results of a prospective nationwide survey.For the Group of Epidemiology of the French Association for the study of the liver (AFEF) Hepatology. 2000;32:477–81.
    1. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: An audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut. 1995;36:437–41.
    1. Smith BC, Desmond PV. Outpatient liver biopsy using ultrasound guidance and the biopty gun is safe and cost effective. Aust N Z J Med. 1995;25:209–11.
    1. Gheorghe L, Iacob S, Gheorghe C. Liver biopsy under ultrasound control for diffuse liver disease - toward a faster, safer, cost-effective and easy acceptable procedure. Rom J Gastroenterol. 2005;14:97–8.
    1. Douds AC, Joseph AE, Finlayson C, Maxwell JD. Is day case liver biopsy underutilised? Gut. 1995;37:574–5.
    1. Spiezia S, Salvio A, Di Somma C, Scelzi C, Assanti AP, Giannattasio F, et al. The efficacy of liver biopsy under ultrasonographic guidance on an outpatient basis. Eur J Ultrasound. 2002;15:127–31.
    1. Zamcheck N, Klausenstock O. Liver biopsy (concluded). II. The risk of needle biopsy. N Engl J Med. 1953;249:1062–9.
    1. Thaler H. [On advantages and dangers of the menghini method of liver biopsy] Wien Klin Wochenschr. 1964;76:533–8.
    1. Lindner H. [Limitations and hazards of percutaneous liver biopsy with the Menghini needle.Experiences with 80,000 liver biopsies] Dtsch Med Wochenschr. 1967;92:1751–7.
    1. McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology. 1990;99:1396–400.
    1. Lee SP, Tasman-Jones C, Wattie WJ. Traumatic hemobilia: A complication of percutaneous liver biopsy. Gastroenterology. 1977;72:941–4.
    1. Lin CL, Chang JJ, Lee TS, Lui KW, Yen CL. Gallbladder polyp as a manifestation of hemobilia caused by arterial-portal fistula after percutaneous liver biopsy: A case report. World J Gastroenterol. 2005;14:305–7.
    1. Malnick S, Melzer E. Routine ultrasound-guided liver biopsy: A time whose idea has come? J Clin Gastroenterol. 2005;39:900–3.
    1. Vautier G, Scott B, Jenkins D. Liver biopsy: Blind or guided? BMJ. 1994;309:1455–6.
    1. Pasha T, Gabriel S, Therneau T, Dickson ER, Lindor KD. Cost-effectiveness of ultrasound-guided liver biopsy. Hepatology. 1998;27:1220–6.
    1. Younossi ZM, Teran JC, Ganiats TG, Carey WD. Ultrasound-guided liver biopsy for parenchymal liver disease: An economic analysis. Dig Dis Sci. 1998;43:46–50.
    1. Farrell RJ, Smiddy PF, Pilkington RM, Tobin AA, Mooney EE, Temperley IJ, et al. Guided versus blind liver biopsy for chronic hepatitis C: Clinical benefits and costs. J Hepatol. 1999;30:580–7.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi